Clinical Trial Detail

NCT ID NCT03931291
Title APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Aprea Therapeutics AB
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

APR-246 + Azacitidine

Age Groups: adult senior

No variant requirements are available.